Hematological aspects of a novel 9-aminoanthracycline, amrubicin

Cancer Science

Volumn 94, Issue 12, 2003, Pages 1104-1106

  Obara, Naoshi ^a   Imagawa, Shigehiko ^a   Nakano, Yoko ^a   Yamamoto, Masayuki ^a   Noguchi, Toshihiro ^b   Nagasawa, Toshiro ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

9 AMINOANTHRACYLINE; AMRUBICIN; ANTHRACYCLINE DERIVATIVE; DOXORUBICIN; UNCLASSIFIED DRUG;

ANEMIA; ANIMAL EXPERIMENT; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; COLONY FORMING UNIT GM; CONTROLLED STUDY; LEUKOCYTE COUNT; LEUKOPENIA; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; THROMBOCYTOPENIA;

ANEMIA; ANIMALS; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; BLOOD PLATELETS; BONE MARROW; COLONY-FORMING UNITS ASSAY; DOXORUBICIN; ERYTHROCYTES; GRANULOCYTES; HEMATOCRIT; HEMATOPOIETIC STEM CELLS; HEMOGLOBINS; LEUKOPENIA; MICE; MICE, INBRED ICR; MONOCYTES;

EID: 0347029603     PISSN: 13479032     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2003.tb01407.x     Document Type: Article

References (11)

1. Ishizumi K, Ohashi N, Tanno N. Stereospecific total synthesis of 9-aminoanthracyclines(+)-9-amino-9-deoxydaunomycin and related compounds. J Org Chem, 1987; 52: 4477-85.
2. Morisada S, Yanagi Y, Noguchi T, Kashiwazaki Y, Fukui M. Antitumor activities of a novel 9-aminoanthracycline (SM-5887) against mouse experimental tumors and human tumor xenografts. Jpn J Cancer Res 1989; 80: 69-76.
3. Yana T, Neguro S, Takada Y, Yokota S, Fukuoka M, the West Japan Lung Cancer Group. Phase II study of amrubicin (SM-5887), a 9-amino-anthracycline, in previously untreated patients with extensive stage small-cell lung cancer (ES-SCLC): a west Japan lung cancer group trial. Am Soc Clin 34th Annu Meet 1998; #1734.
4. Hiraki S, Shinkai T, Furuse K, Fukuoka M, Ohnoshi T, Kimura I, the SM-5887 Lung Cancer Study Group. A phase II study of SM-5887, a novel 9-aminoanthracycline, for non-small cell lung cancer. 18th Int Congr Chemother 1993; #726A.
5. Akutsu M, Kano Y, Ogawa M, Miura A, Hirano M, Masaoka T, Tatsumi N. Late phase II clinical study of amrubicin hydrochloride, a novel synthetic anthracycline derivative anticancer agent, for malignant lymphoma. Jpn J Cancer Chemother 2001; 28: 1867-76.
6. Masaoka T, Ogawa M, Inoue K, Sanpi K, Kuraishi Y, Toki H, Tamura K, Takagi T, Shibata A, Hirano M, Ezaki K, Shirakawa S, Matsuda T, Kimura I. Eariy phase II clinical trial of amrubicin hydrochloride in patients with malignant lymphoma. Jpn J Cancer Chemother 2001; 28: 1857-65.
7. Yamaoka T, Hanada M, Ichii S, Morisada S, Noguchi T, Yanagi Y. Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells. Jpn J Cancer Res 1998; 89: 1067-73.
8. Noguchi T, Ichii S, Morisada S, Yamaoka T, Yanagi Y. In vivo efficacy and tumor-selective metabolism of amrubicin to its active metabolite. Jpn J Cancer Res 1998; 89: 1055-60.
9. Noguchi T, Ichii S, Morisada S, Yamaoka T, Yanagi Y. Tumor-selective distribution of an active metabolite of the 9-aminoanthracycline amrubicin. Jpn J Cancer Res 1998; 89: 1061-6.
10. Morisada S, Yanagi Y, Kashiwazaki Y, Fukui M. Toxicological aspects of a novel 9-aminoanthracycline, SM-5887. Jpn J Cancer Res 1989; 80: 77-82.
11. Suzuki T, Arai M, Iwasaki T, Yamamoto H, Kanda H. The cardiotoxicity of a new anthracycline, SM-5887, in rabbits. Proc Jpn Cancer Assoc 46th Annu Meet 1987; 447.